Daily Stock Analysis, BLCM, Bellicum Pharmaceuticals Inc, priceseries

Bellicum Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
8.36
Close
7.96
High
8.41
Low
7.68
Previous Close
8.48
Daily Price Gain
-0.52
YTD High
27.90
YTD High Date
Jan 17, 2020
YTD Low
3.32
YTD Low Date
Mar 16, 2020
YTD Price Change
-7.14
YTD Gain
-47.28%
52 Week High
27.90
52 Week High Date
Jan 17, 2020
52 Week Low
3.32
52 Week Low Date
Mar 16, 2020
52 Week Price Change
-8.24
52 Week Gain
-50.86%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 16. 2017
140.90
Mar 21. 2017
148.20
3 Trading Days
5.18%
Link
LONG
Jun 16. 2017
113.30
Jun 29. 2017
122.94
9 Trading Days
8.51%
Link
LONG
Aug 28. 2017
94.20
Sep 21. 2017
110.10
17 Trading Days
16.88%
Link
LONG
Feb 16. 2018
66.00
Mar 19. 2018
76.85
20 Trading Days
16.44%
Link
LONG
Apr 11. 2018
68.50
Apr 18. 2018
77.30
5 Trading Days
12.85%
Link
LONG
May 31. 2018
80.80
Jun 18. 2018
91.61
12 Trading Days
13.37%
Link
LONG
Aug 16. 2018
64.10
Sep 5. 2018
68.31
13 Trading Days
6.57%
Link
LONG
Dec 19. 2019
10.00
Jan 24. 2020
17.66
23 Trading Days
76.57%
Link
LONG
Apr 6. 2020
4.80
Apr 21. 2020
5.59
10 Trading Days
16.45%
Link
LONG
May 7. 2020
5.58
May 13. 2020
5.95
4 Trading Days
6.63%
Link
Company Information
Stock Symbol
BLCM
Exchange
NasdaqGM
Company URL
http://www.bellicum.com
Company Phone
(832) 384-1100
CEO
Richard A. Fair
Headquarters
Texas
Business Address
2130 WEST HOLCOMBE BOULEVARD, SUITE 800, HOUSTON, TX 77030
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001358403
About

Bellicum Pharmaceutivals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The company develops chemical induction of dimerization technology platform to engineer and control components of the immune system. Bellicum Pharmaceutivals was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.